Marie Debrue
Senior Director, In Vivo Sciences, Preclinical development at Regeneron Cell Medicine
- Role
- Senior Director in Vivo Sciences, Regeneron Cell Medicine at Regeneron
- Location
- Cambridge, MA, US
- LinkedIn followers
- 500 followers
About Marie Debrue
Accomplished scientific and strategic leader with over 20 years of experience in preclinical development and in vivo pharmacology across CRO, biotech, and pharmaceutical settings. Proven track record of advancing autologous and in vivo CAR/TCR T cell therapies from early discovery to IND submission for oncology and autoimmune indications. Expert in leading and inspiring large high-performing teams, driving IND strategy and delivering rigorous nonclinical data packages that support successful first-in-human studies. Recognized for optimizing cross-functional workflows, redefining portfolio governance, and streamlining nonclinical development to accelerate IND timelines and enhance resource alignment.• Proven track record in building and leading high-performing, diverse teams with consistently high engagement scores• Deep expertise in in vivo pharmacology and nonclinical development strategy• Strong experience in regulatory interactions, including IND submissions• Committed to operational excellence and strategic leadership through continuous improvement and process optimization in GLP and non-GLP settings• Successfully established and led animal care programs with impeccable regulatory compliance• Skilled in talent development, change management, and cross-functional collaboration
Experience
Senior Director in Vivo Sciences, Regeneron Cell Medicine
Apr 2024 — Present · Cambridge, MA, US
Built and lead the in vivo sciences organization consisting of PhD in vivo pharmacologists, research associate scientists, operation managers and technicians (up to 25 colleagues) responsible for the vivarium operation, animal model development and in vivo strategy and data generation from early discovery research to IND. • Advanced four cell therapy programs from proof-of-concept to first-in-human studies delivering robust preclinical data packages supporting 3 US IND filings for both liquid and solid tumor indications and 1 Chinese IIT (Investigator Initiated Trial).• Champion multiple strategic and operational excellence initiatives such as designed and implemented Regeneron Cell Medicine (RCM) post-acquisition decision making framework preserving efficiency and nimbleness while integrating enterprise systems, led cross-functional process optimization initiatives that reduced timelines from target nomination to IND by 25%(4 → 3 years) through identification of interdependencies and elimination of cross-functional bottlenecks; defined and established strategic milestones for Regeneron’s cell therapy portfolio. • Authored and reviewed key regulatory documents, including pre-IND briefing books and IND Modules 2 and 4 ensuring scientific rigor and regulatory compliance.• Established and lead the internal animal care program and vivarium operations serving as Attending Veterinarian gaining and maintaining full accreditation and ensuring local regulatory compliance.
Education
Université de Montréal
Master in Sciences, Veterinary/immunology/respiratory
2002 — 2004
University of Liège
Doctor, Veterinary Medicine
1995 — 2001
Skills
- Animal Models
- Vaccines
- Toxicology
- Veterinary Medicine
- Oncology
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.